Saturday, 5 September 2015

ILCA Symposium 3: Advances in Transarterial Treatment of HCC

Chairs: Peter R. Galle, MD, PhD (Germany) and Richard Finn, MD (USA)

  • Riccardo Lencioni, MD, PhD (Italy)

    Transarterial chemoembolisation (TACE) is the most widely used treatment for hepatocellular carcinoma (HCC) worldwide. A meta-analysis of randomised trials has established TACE as the standard of care for patients classified as intermediate-stage according to the Barcelona Clinic for Liver Cancer (BCLC) staging system. The most popular TACE technique is the administration of an anticancer-in-oil emulsion followed by embolic agents.

  • Riad Salem, MD (USA)

    Treatment options for liver tumours that cannot be resected are based on transarterial techniques. Y90 microspheres represent one of those transarterial options. During the past 15 years, numerous studies involving larger cohorts, comparative effectiveness and small randomized studies have provided evidence of the safety and efficacy of Y90 in HCC.

  • Thierry de Baere, MD (France)

    Conventional TACE (c-TACE) using Lipiodol with doxorubicin or cisplatinum is established as a standard of care in intermediate stage HCC, due to positive results of randomized controlled trials published in 2002. Since this publication, no treatment has been demonstrated superior.
    However, many advances have been carried out by the medical community including: new compound to deliver intra-arterially, new technologies in image guidance, and refinement in patient selection.

  • Jean-François Geschwind, MD (USA)

    Hepatocellular carcinoma (HCC) is one of the most highly lethal malignancies in the world, making it the third most common cause of cancer related mortality worldwide. In the United States, the incidence of HCC is on the rise, secondary to a concomitant rise in hepatitis C viral (HCV) infection; in the past 2 decades the incidence of HCV-related HCC has tripled.